Eli Lilly, Amylin: exenatide as effective as NovoMix30 in controlling blood sugar

By Lisa Kerner

Charlotte, N.C., Sept. 14 - Eli Lilly and Co. and Amylin Pharmaceuticals, Inc. announced results from a 52-week study indicating that exenatide improves blood sugar levels as effectively as biphasic insulin aspart 30/70 (NovoMix30, NovoNordisk) in type 2 diabetes patients who could not achieve blood sugar control on both metformin and a sulfonylurea.

In the study, 32% of subjects using exenatide reached the target HbA1C (blood glucose level) of 7% or less, compared with only 24% of subjects in the biphasic insulin aspart group. Additionally, subjects using exenatide lost an average of 5.5 pounds, and subjects in the biphasic insulin aspart group gained an average of 6.4 pounds.

The study results were presented at the 42nd annual meeting of the European Association of the Study of Diabetes in Copenhagen, Denmark. The 501-patient study is the second long-term European clinical trial demonstrating exenatide's effectiveness compared to insulin.

Eli Lilly is a pharmaceutical company based in Indianapolis, Ind., and Amylin is a biopharmaceutical company based in San Diego, Calif.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.